Governance Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 09/02/2026 GMT			5-day change	1st Jan Change
320.00 ^USD	-2.49%		-5.34%	-19.53%

01-27	Intellia gets FDA nod to resume one gene therapy trial after safety pause	RE
01-20	RBC Cuts Price Target on Alnylam Pharmaceuticals to $465 From $500, Keeps Outperform Rating	MT

Executive Committee: Alnylam Pharmaceuticals, Inc.

Manager

Positions heldSince

Yvonne Greenstreet

63 year

Chief Executive Officer

31/12/2021

Robert Hesslein

73 year

General Counsel	31/08/2024
Corporate Secretary	31/08/2024

Kevin Fitzgerald

58 year

Chief Tech/Sci/R&D Officer

31/08/2016

Joshua Brodsky

Investor Relations Contact	31/01/2021
Public Communications Contact	31/01/2021

Melissa McLaughlin

Human Resources Officer

31/12/2024

Pushkal Garg

58 year

Chief Tech/Sci/R&D Officer

28/10/2014

Jeffrey Poulton

58 year

Comptroller/Controller/Auditor	12/08/2019
Director of Finance/CFO	12/08/2019

Timothy J. Maines

Chief Tech/Sci/R&D Officer

31/03/2023

Piyush Sharma

Compliance Officer

20/09/2022

Composition of the Board of Directors: Alnylam Pharmaceuticals, Inc.

Director

CommitteesSince

Amy Schulman

65 year

Governance Committee
Nominating Committee
Compensation Committee	30/06/2015
Audit Committee	11/01/2026
Compensation Committee Chair	24/01/2021
Finance Committee	11/01/2026

Colleen Reitan

66 year

Audit Committee	24/09/2019
Compensation Committee Chair
HR Committee Chair
Compensation Committee	25/08/2019
Finance Committee	24/09/2019
Governance Committee Chair	24/09/2019
Nominating Committee Chair	24/09/2019

David Pyott

72 year

Executive Committee	06/04/2011
Governance Committee Chair
Nominating Committee Chair
Audit Committee
Governance Committee
Nominating Committee

Dennis Ausiello

80 year

Governance Committee
Nominating Committee	29/12/2021
Audit Committee	29/12/2021
Compensation Committee	29/12/2021
Finance Committee	29/12/2021

Charles Sigal

74 year

Governance Committee	07/06/2020
Nominating Committee	07/06/2020
Compensation Committee
HR Committee

Olivier Brandicourt

70 year

Audit Committee	21/01/2024
Compensation Committee	01/03/2020
HR Committee	01/03/2020

Margaret Hamburg

70 year

Governance Committee	09/01/2019
Nominating Committee	09/01/2019

Stuart Arbuckle

60 year

Executive Committee
Compensation Committee	23/07/2019

Peter Kellogg

68 year

Audit Committee Chair

28/09/2023

Yvonne Greenstreet

63 year

Director/Board Member

27/10/2021

Latest Appointments: Alnylam Pharmaceuticals, Inc.

01-08	Praxis Precision Medicines, Inc. Announces Management Changes	CI
12-10	Elevance Health Announces Appointment of Amy Schulman as Independent Director, Effective January 12, 2026	CI
12-03	Alnylam Pharmaceuticals Announces Changes to Board of Directors	CI
12-03	Alnylam Pharmaceuticals announces changes to board of directors	RE
18/06/25	Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	CI
28/05/25	Transcode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board	CI
05/03/25	Alnylam Pharmaceuticals, Inc. Announces Retirement of Phillip A. Sharp from the Board of Directors, Effective May 8, 2025	CI

More news

Former Officers and Directors: Alnylam Pharmaceuticals, Inc.

Insider

Positions held

SinceUntil

Michael Bonney

Director/Board Member	04/01/2023	01/12/2025
Chairman	30/11/2015	04/01/2023
Independent Dir/Board Member	16/12/2014	04/01/2023

Phillip Sharp

Director/Board Member	13/06/2002	07/05/2025
Founder	13/06/2002	07/05/2025
Independent Dir/Board Member	13/06/2002	07/05/2025

Akshay Vaishnaw

Chief Tech/Sci/R&D Officer	31/12/2005	03/01/2022
Corporate Officer/Principal	01/10/2023	30/11/2024
President	03/01/2022	01/10/2023

James Bilotta

Chief Tech/Sci/R&D Officer

30/09/2015

31/07/2024

Sara Nochur

General Counsel	31/12/2005	31/12/2020
Corporate Officer/Principal	31/12/2020	30/04/2024

Marsha Fanucci

Director/Board Member	07/12/2010	28/09/2023
Independent Dir/Board Member	07/12/2010	28/09/2023

Al Boyle

Chief Tech/Sci/R&D Officer

30/11/2015

31/03/2023

Steven Paul

Director/Board Member	21/09/2010	15/04/2022
Independent Dir/Board Member	21/09/2010	15/04/2022

John Maraganore

Director/Board Member	30/11/2002	30/12/2021
Chief Executive Officer	30/11/2002	30/12/2021
Founder	30/11/2002	30/12/2021
President	30/11/2002	30/11/2007

Laurie Keating

General Counsel	16/09/2014	09/09/2021
Corporate Secretary	16/09/2014	09/09/2021

Barry Greene

Chief Operating Officer	30/09/2003	18/09/2016
President	30/09/2003	29/09/2020

Paul Schimmel

Director/Board Member	13/06/2002	05/05/2020
Founder	13/06/2002	05/05/2020
Independent Dir/Board Member	13/06/2002	05/05/2020

Nereyda Garcia

Compliance Officer

31/12/2015

30/11/2019

Mike Mason

Comptroller/Controller/Auditor	30/11/2005	30/09/2018
Director of Finance/CFO	01/12/2005	31/05/2016
Treasurer	31/01/2011	31/01/2019

John Clarke

Director/Board Member	13/06/2002	09/01/2019
Chairman	13/06/2002	31/12/2015
Founder	13/06/2002	09/01/2019
Independent Dir/Board Member	13/06/2002	09/01/2019

Karen Anderson

Human Resources Officer

16/09/2014

31/12/2018

Kevin Starr

Director/Board Member	31/08/2003	28/02/2018
Independent Dir/Board Member	31/08/2003	28/02/2018

David-Alexandre Gros

Director of Finance/CFO	30/06/2016	05/01/2017
Corporate Officer/Principal	07/06/2015	30/06/2016

Mark Baglin

Sales & Marketing

31/12/2016

Benny Sorensen

Chief Tech/Sci/R&D Officer

30/06/2015

30/09/2016

Susanna High

Director/Board Member	31/01/2007	31/05/2008
Corporate Officer/Principal	31/05/2008	31/08/2016

Emmanuel Dulac

Corporate Officer/Principal

18/08/2016

Oved Amitay

Corporate Officer/Principal

26/06/2012

31/05/2016

Arianna Greco

General Counsel	31/12/2015	-
Corporate Officer/Principal	31/12/2015	-

Laurence Reid

Corporate Officer/Principal

03/06/2010

30/12/2014

Marko Kinchen Kozul

Corporate Officer/Principal

16/09/2014

Victor J. Dzau

Director/Board Member	31/03/2007	29/06/2014
Independent Dir/Board Member	31/03/2007	29/06/2014

Varun Kumar

Corporate Officer/Principal

31/03/2011

31/01/2014

Pritesh Gandhi

Chief Tech/Sci/R&D Officer

31/12/2013

Aria Tavana

Corporate Officer/Principal

31/12/2012

Nessan Bermingham

Corporate Officer/Principal

29/04/2012

Dinah Sah

Chief Tech/Sci/R&D Officer	31/03/2005	31/12/2011
Private Equity Investor	31/12/2009	31/12/2011

Kenneth S. Koblan

Chief Tech/Sci/R&D Officer	19/12/2010	01/06/2011
Corporate Officer/Principal	03/06/2010	19/12/2010

Vicki Sato

Director/Board Member

30/11/2005

29/04/2011

Patricia Allen

Director of Finance/CFO	30/04/2004	26/09/2010
Treasurer	30/04/2004	27/02/2011

James L. Vincent

Director/Board Member

30/06/2005

21/09/2010

Garvin L. Warner

Corporate Officer/Principal

31/07/2010

Ed Scolnick

Director/Board Member

31/01/2008

31/01/2010

Antonin Rollet de Fougerolles

Chief Tech/Sci/R&D Officer

31/12/2002

31/12/2009

Jason Rhodes

Corporate Officer/Principal

30/06/2007

31/12/2009

John Schmidt

Chief Tech/Sci/R&D Officer

30/09/2008

29/09/2009

Peter J. Williams

Corporate Officer/Principal

31/12/2005

Nagesh Mahanthappa

Corporate Officer/Principal

31/07/2002

31/01/2007

Mary DeLena

Corporate Officer/Principal

31/12/2006

Eric W. Raichle

Human Resources Officer

31/12/2006

John Berriman

Director/Board Member

30/06/2003

06/12/2005

Cynthia Clayton

Investor Relations Contact

31/12/2004

Robert A. Millman

Corporate Officer/Principal

08/09/2004

Thomas R. Ulich

Chief Tech/Sci/R&D Officer

31/12/2002

31/12/2003

Lubomir Nechev

Corporate Officer/Principal

31/12/2003

Vincent J. Miles

Corporate Officer/Principal

30/06/2003

Victor E. Kotelianski

Corporate Officer/Principal

31/03/2003

David M. Konys

Corporate Officer/Principal

31/03/2003

Rachel Meyers

Chief Tech/Sci/R&D Officer

31/03/2003

Peter Barrett

Director/Board Member

30/06/2002

Eric Ruby

General Counsel

Mary D. Trueblood

Comptroller/Controller/Auditor

Philip T. Chase

General Counsel

Kathryn Morris

Public Communications Contact

Roy R. Lobb

Corporate Officer/Principal

Edward E. Harlow

Corporate Officer/Principal

David Altreuter

Corporate Officer/Principal

Jeffrey Behrens

Corporate Officer/Principal

Jian Xin Chen

Corporate Officer/Principal

David Neafus

Director of Finance/CFO

Christoph Westphal

Director/Board Member	-	-
Founder	-	-

Zachary A. Zimmerman

Corporate Officer/Principal

Jürgen Soutschek

Chief Tech/Sci/R&D Officer

Ulrich Bodner

Corporate Officer/Principal

Stuart Pollard

Corporate Officer/Principal

Donna T. Ward

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	22
Female	5

Of which Executive Committee

Male	8
Female	1

Of which Directors

Male	8
Female	2

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

Employees

2,230

Sector

Pharmaceuticals

Calendar

02-12 - Q4 2025 Earnings Release

More about the company